Valuation dashboard for BeOne Medicines AG (ONC) with P/E 5.22, P/B 10.68, EV/EBITDA 32.02 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult...
Analysis Summary
BeOne Medicines AG reported revenue of $5.34B in the most recent fiscal year, growing at a 5-year CAGR of 76.8%.
Trailing-twelve-month margins: gross margin 87.8%, operating margin 15.1%, net margin 10.7%.
At $377.63 (closing price, October 28, 2026), ONC trades at a P/E of 5.22 and an ROE of 14.27%. Market capitalisation stands at $40.4B, placing it among large-cap names.
Balance sheet quality for ONC: current ratio of 3.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 5.22 |
| Price / Book | 10.68 |
| EV / EBITDA | 32.02 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3,580.02 |
| vs Current Price | -1,048.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ONC | BeOne Medicines AG | $40.4B | 5.22 | 10.68 | 14.3% |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.3B | 30.83 | 6.64 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| MRNA | Moderna, Inc. | $85.5B | 12.54 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.7B | 20.12 | 2.65 | 13.8% |
| ARGX | argenx SE | $54.7B | 41.71 | 6.61 | 16.9% |
| 0QNO.L | Lonza Group AG | $43.8B | 5.43 | -1.3% |
Price
| Price | $377.63 (closing price, October 28, 2026) |
| Market Cap | $40.4B |
| Exchange | NASDAQ |
| Country | CH |
Profitability
| Return on Equity | 14.27% |
| Return on Invested Capital | 9.63% |
| Return on Assets | 7.17% |
| Gross Margin | 87.82% |
| Operating Margin | 15.05% |
| Net Margin | 10.68% |
Related companies: VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ONC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks